A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein (a)

Conditions

Cardiovascular disease (atherosclerotic cardiovascular disease (ASCVD) and elevated lipoprotein (a))

Brief summary

Time to CHD death, myocardial infarction, or urgent coronary revascularization, whichever occurs first

Detailed description

Time to cardiovascular death, myocardial infarction, or ischemic stroke, whichever occurs first, Time to cardiovascular death, myocardial infarction, urgent coronary revascularization, or ischemic stroke, whichever occurs first, Percent change from baseline to week 48 in Lp(a), • time to myocardial infarction • time to CHD death or myocardial infarction, whichever occurs first • time to urgent coronary revascularization • time to coronary revascularization • time to CHD death • time to cardiovascular death • time to death by any cause • time to ischemic stroke, Treatment-emergent adverse events (including clinically significant changes in laboratory values and vital signs), serious adverse events, and adverse events leading to discontinuation of investigational product, serum concentration of olpasiran at selected timepoints

Related papers

No related papers found yet.

Interventions

DRUGPlacebo for AMG 890

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Time to CHD death, myocardial infarction, or urgent coronary revascularization, whichever occurs first	—

Secondary

Measure	Time frame
Time to cardiovascular death, myocardial infarction, or ischemic stroke, whichever occurs first, Time to cardiovascular death, myocardial infarction, urgent coronary revascularization, or ischemic stroke, whichever occurs first, Percent change from baseline to week 48 in Lp(a), • time to myocardial infarction • time to CHD death or myocardial infarction, whichever occurs first • time to urgent coronary revascularization • time to coronary revascularization • time to CHD death • time to cardiovascular death • time to death by any cause • time to ischemic stroke, Treatment-emergent adverse events (including clinically significant changes in laboratory values and vital signs), serious adverse events, and adverse events leading to discontinuation of investigational product, serum concentration of olpasiran at selected timepoints	—

Measure

Time frame

Time to cardiovascular death, myocardial infarction, or ischemic stroke, whichever occurs first, Time to cardiovascular death, myocardial infarction, urgent coronary revascularization, or ischemic stroke, whichever occurs first, Percent change from baseline to week 48 in Lp(a), • time to myocardial infarction • time to CHD death or myocardial infarction, whichever occurs first • time to urgent coronary revascularization • time to coronary revascularization • time to CHD death • time to cardiovascular death • time to death by any cause • time to ischemic stroke, Treatment-emergent adverse events (including clinically significant changes in laboratory values and vital signs), serious adverse events, and adverse events leading to discontinuation of investigational product, serum concentration of olpasiran at selected timepoints

—

Countries

Austria, Belgium, Bulgaria, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Italy, Lithuania, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Spain, Sweden

Outcome results

None listed